Table of Contents:

1 Report Prologue
2 Executive Summary
3 Market Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.3.1 Assumptions
3.3.2 Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Growing geriatric population and increasing prevalence of age-related macular degeneration
5.2.2 Several branded drugs going off patent
5.3 Restraints
5.3.1 High cost associated with AMD
5.3.2 Stringent FDA regulations
5.4 Opportunities
5.4.1 Strong pipeline
5.5 Pipeline Analysis
5.5.1 Brolucizumab 6 mg
5.5.2 NCT01691261
5.5.3 NCT03102138
5.5.4 Lampalizumab
5.5.5 RG7716
5.5.6 Emixustat
5.5.7 Zimura Dry AMD
5.5.8 Zimura Wet AMD
5.5.9 GSK933776
5.5.10 RXI-109
5.5.11 Abicipar Pegol
6 Market Factor Analysis
6.1 Supply Chain Analysis
6.1.1 R&D
6.1.2 Parts Manufacturing
6.1.3 Distribution
6.1.4 Marketing & Sales
6.1.5 Post-Sales Monitoring
6.2 Porter's Five Forces Analysis
6.2.1 Bargaining Power of Suppliers
6.2.2 Bargaining Power of Buyers
6.2.3 Threat of New Entrants
6.2.4 Threat of Substitutes
6.2.5 Intensity of Rivalry
7 Global Age-Related Macular Degeneration Market, by Type
7.1 Overview
7.1.1 Introduction
7.1.2 Wet Age-Related Macular Degeneration (Wet AMD)
7.1.3 Dry Age-Related Macular Degeneration (Dry AMD)
8 Global Age-Related Macular Degeneration Market, by Stages
8.1 Overview
8.1.1 Introduction
8.1.2 Intermediate stage age-related macular degeneration
8.1.3 Early-stage age-related macular degeneration
8.1.4 Late stage age-related macular degeneration
9 Global Age-Related Macular Degeneration Market, by Age Group
9.1 Overview
9.1.1 Introduction
9.1.2 Above 75 years
9.1.3 Above 60 years
9.1.4 Above 40 years
10 Global Age-Related Macular Degeneration Market, by Diagnosis & Treatment
10.1 Overview
10.1.1 Introduction
10.1.2 Treatment
10.1.3 Diagnosis
11 Global Age-Related Macular Degeneration Market, by Route of Administration
11.1 Overview
11.1.1 Introduction
11.1.2 Intravitreal route of administration
11.1.3 Intravenous route of administration
12 Global Age-Related Macular Degeneration Market, By End-User
12.1 Overview
12.1.1 Introduction
12.1.2 Hospital & Clinics
12.1.3 Diagnostic Centers
12.1.4 Academic research institutes
13 Age-Related Macular Degeneration Market, by Region
13.1 Introduction
13.2 Americas
13.2.1 North America
13.2.1.1 U.S.
13.2.1.2 Canada
13.2.2 South America
13.3 Europe
13.3.1 Western Europe
13.3.1.1 Germany
13.3.1.2 France
13.3.1.3 U.K
13.3.1.4 Italy
13.3.1.5 Spain
13.3.1.6 Rest of Western Europe
13.3.2 Eastern Europe
13.4 Asia Pacific
13.4.1 Japan
13.4.2 China
13.4.3 India
13.4.4 Australia
13.4.5 Republic of Korea
13.4.6 Rest of Asia Pacific
13.5 The Middle East and Africa
13.5.1 Middle East
13.5.2 Africa
14 Competitive Landscape
14.1 Company Market Share Analysis
14.1.1 Introduction
14.2 Key Strategic Analysis
14.2.1 Introduction
15 Company Profiles
15.1 Novartis AG
15.1.1 Company Overview
15.1.2 Financial Overview
15.1.3 Products Offering
15.1.4 Key Developments
15.1.5 SWOT Analysis
15.1.6 Key Strategy
15.2 Pfizer Inc.
15.2.1 Company Overview
15.2.2 Financial Overview
15.2.3 Products Offering
15.2.4 Key Developments
15.2.5 SWOT Analysis
15.2.6 Key Strategy
15.3 F. Hoffmann-La Roche AG
15.3.1 Company Overview
15.3.2 Financial Overview
15.3.3 Products Offering
15.3.4 Key Developments
15.3.5 SWOT Analysis
15.3.6 Key Strategy
15.4 Acucela Inc.
15.4.1 Company Overview:
15.4.2 Financial Overview
15.4.3 Products Offering
15.4.4 Key Developments
15.4.5 SWOT Analysis
15.4.6 Key Strategy
15.5 Ophthotech Corporation
15.5.1 Company Overview
15.5.2 Financial Overview
15.5.3 Products Offering
15.5.4 Key Developments
15.5.5 SWOT Analysis
15.5.6 Key Strategy
15.6 GlaxoSmithKline Plc.
15.6.1 Company Overview
15.6.2 Financial Overview
15.6.3 Products Offering
15.6.4 Key Developments
15.6.5 SWOT Analysis
15.6.6 Key Strategy
15.7 Bayer AG
15.7.1 Company Overview
15.7.2 Financial Overview
15.7.3 Products Offering
15.7.4 Key Developments
15.7.5 SWOT Analysis
15.7.6 Key Strategy
15.8 Rxi Pharmaceuticals, Inc.
15.8.1 Company Overview
15.8.2 Financial Overview
15.8.3 Pipeline Products
15.8.4 Key Developments
15.8.5 SWOT Analysis
15.8.6 Key Strategy
15.9 Regeneron Pharmaceutical Inc.
15.9.1 Company Overview
15.9.2 Financial Overview
15.9.3 Products Offering
15.9.4 Key Developments
15.9.5 SWOT Analysis
15.9.6 Key Strategy
15.1 Alimera Sciences Inc.
15.10.1 Company Overview
15.10.2 Financial Overview
15.10.3 Pipeline Products
15.10.4 Key Developments
15.10.5 SWOT Analysis
15.10.6 Key Strategy
15.11 Santen Pharmaceuticals co.
15.11.1 Company Overview
15.11.2 Financial Overview
15.11.3 Products Offering
15.11.4 SWOT Analysis
15.11.5 Key Developments
15.11.6 Key Strategy
15.12 ALLERGAN
15.12.1 Company Overview
15.12.2 Financial Overview
15.12.3 Products Offering
15.12.4 SWOT Analysis
15.12.5 Key Developments
15.12.6 Key Strategy
15.13 Bausch & Lomb Incorporated
15.13.1 Company Overview
15.13.2 Financial Overview
15.13.3 Products Offering
15.13.4 Key Developments
15.13.5 SWOT Analysis
15.13.6 Key Strategy
16 Appendix
16.1 Discussion Blue Print